FDA rejects Aricept skin patch for Alzheimer's disease

04/25/2011 | Pharmaceutical Business Review Online · MedCityNews.com

The FDA declined to approve Eisai and Teikoku Pharma's weekly transdermal-patch version of Aricept, a treatment for Alzheimer's disease. The companies will review the agency's complete-response letter to determine their next step, Eisai said.

View Full Article in:

Pharmaceutical Business Review Online · MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX